Ypsomed Holding AG

Ypsomed Holding AG is a Swiss medical technology firm specializing in the development, manufacturing, and global distribution of advanced injection and infusion systems, primarily serving pharmaceutical and biotechnology companies. The enterprise operates through two primary segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment, identified by the YDS brand, provides a diverse range of sophisticated self-injection and infusion devices, including pen, auto, patch, and wearable injectors, alongside other smart medical solutions. Conversely, the Ypsomed Diabetes Care segment, recognized by its mylife brand, offers crucial products for diabetes management, encompassing insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, and a range of complementary accessories. Additionally, Ypsomed provides precision-turned components, contract manufacturing, and various other services. Its market presence is established through collaborations with biotechnology and pharmaceutical partners, alongside its own distribution network and independent distributors. The company maintains a global presence, operating in Switzerland, across Europe, North America, and numerous other international regions. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

CEO: Simon Michel - https://www.ypsomed.com